TargetMol

BTdCPU

Product Code:
 
TAR-T7150
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7150-1mg1mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-1mL1 mL * 10 mM (in DMSO)£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-5mg5mg£326.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-10mg10mg£464.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7150-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BTdCPU is a potent activator of heme-regulated eIF2α kinase (HRI) .?BTdCPU promotes eIF2α phosphorylation and induced apoptosis in resistant cell.
CAS:
1257423-87-2
Formula:
C13H8Cl2N4OS
Molecular Weight:
339.19
Pathway:
Apoptosis; Metabolism
Purity:
0.9861
SMILES:
Clc1ccc(NC(=O)Nc2ccc3nnsc3c2)cc1Cl
Target:
Apoptosis; Phosphatase; PERK

References

Burwick N, Zhang MY,et al.The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma[J].Leuk Res. 2017 Apr;55:23-32.